C Jackisch

530 total citations
35 papers, 360 citations indexed

About

C Jackisch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C Jackisch has authored 35 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in C Jackisch's work include Breast Cancer Treatment Studies (18 papers), Advanced Breast Cancer Therapies (17 papers) and Cancer Treatment and Pharmacology (11 papers). C Jackisch is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), Advanced Breast Cancer Therapies (17 papers) and Cancer Treatment and Pharmacology (11 papers). C Jackisch collaborates with scholars based in Germany, Switzerland and United Kingdom. C Jackisch's co-authors include Michael Untch, H. P. G. Schneider, Achim Rody, Holger Eidtmann, G von Minckwitz, Jens‐Uwe Blohmer, M. Kaufmann, Serban Dan Costa, Volker Möbus and Andreas du Bois and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Obstetrics & Gynecology and Reproductive Biology.

In The Last Decade

C Jackisch

32 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C Jackisch Germany	10	219	142	104	88	66	35	360
Marie‐Pierre Chauvet France	11	96 0.4×	176 1.2×	44 0.4×	120 1.4×	31 0.5×	26	299
Bénédicte Lesieur France	10	180 0.8×	179 1.3×	124 1.2×	142 1.6×	19 0.3×	18	419
Viola Liberale Italy	9	65 0.3×	128 0.9×	111 1.1×	92 1.0×	47 0.7×	19	346
Julie Cuartero Canada	7	139 0.6×	235 1.7×	29 0.3×	165 1.9×	29 0.4×	8	396
M Tomšová Czechia	7	251 1.1×	47 0.3×	56 0.5×	46 0.5×	15 0.2×	22	387
S. Amato Argentina	8	171 0.8×	118 0.8×	18 0.2×	63 0.7×	38 0.6×	12	330
Carmelo Bengala Italy	9	176 0.8×	63 0.4×	46 0.4×	41 0.5×	18 0.3×	19	320
Kim McManus United States	9	107 0.5×	126 0.9×	134 1.3×	100 1.1×	14 0.2×	10	396
Masataka Takenaka Japan	9	96 0.4×	54 0.4×	94 0.9×	67 0.8×	16 0.2×	22	342
Keisuke Nishihara Japan	8	63 0.3×	56 0.4×	100 1.0×	66 0.8×	86 1.3×	10	332

Countries citing papers authored by C Jackisch

Since Specialization

Citations

This map shows the geographic impact of C Jackisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Jackisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Jackisch more than expected).

Fields of papers citing papers by C Jackisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Jackisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Jackisch. The network helps show where C Jackisch may publish in the future.

Co-authorship network of co-authors of C Jackisch

This figure shows the co-authorship network connecting the top 25 collaborators of C Jackisch. A scholar is included among the top collaborators of C Jackisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Jackisch. C Jackisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pondé, Noam, Larissa A. Korde, Florentine Hilbers, et al.. (2019). SERIOUS ADVERSE EVENTS AMONG OLDER PATIENTS IN THE ALTTO TRIAL. Journal of Geriatric Oncology. 10(6). S14–S15.

Wöckel, Achim, PA Fasching, J Heim, et al.. (2019). Abstract OT3-02-01: RIBANNA — Real-world evidence of ribociclib plus aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line therapy for postmenopausal women with HR+, HER2– advanced breast cancer (aBC). Cancer Research. 79(4_Supplement). OT3–2. 1 indexed citations

Furlanetto, Jenny, Christian Thode, Jens Huober, et al.. (2018). Abstract PD7-09: Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC). Cancer Research. 78(4_Supplement). PD7–9. 1 indexed citations

Jackisch, C, M. Piccart, RD Gelber, et al.. (2016). Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis. Cancer Research. 76(4_Supplement). PD5–1. 8 indexed citations

Moebus, Volker, Andreas Schneeweiß, Andreas du Bois, et al.. (2012). Abstract S3-4: Ten year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C)) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with ≥ 4 positive lymph nodes.. Cancer Research. 72(24_Supplement). S3–4. 11 indexed citations

Loibl, Sibylle, Christian Jackisch, Michael Untch, et al.. (2012). Abstract S3-1: Neoadjuvant Chemotherapy in the very young 35 years of age or younger. Cancer Research. 72(24_Supplement). S3–1. 13 indexed citations

Regan, MM, U. Dafni, Dimitris Karlis, et al.. (2012). Abstract P5-18-02: Selective Crossover in Randomized Trials of Adjuvant Trastuzumab for Breast Cancer: Coping with Success. Cancer Research. 72(24_Supplement). P5–18.

Cameron, David, Julia Brown, Rebecca Dent, et al.. (2012). Abstract S6-5: Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Research. 72(24_Supplement). S6–5. 9 indexed citations

Minckwitz, G von, Jens‐Uwe Blohmer, Serban Dan Costa, et al.. (2011). S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial.. Cancer Research. 71(24_Supplement). S3–2. 28 indexed citations

10.

Möbus, Volker, Nadia Harbeck, Dirk Elling, et al.. (2011). S2-4: GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis.. Cancer Research. 71(24_Supplement). S2–4. 18 indexed citations

11.

Minckwitz, G von, M. Kaufmann, Sherko Kümmel, et al.. (2011). PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy.. Cancer Research. 71(24_Supplement). PD07–5. 1 indexed citations

12.

Thill, Marc, Sepp Braun, & C Jackisch. (2008). Benigne multizystische peritoneale Mesotheliome - Eine seltene Differenzialdiagnose bei zystischen Unterbauchtumoren - Zwei Kasuistiken und Literaturübersicht. Geburtshilfe und Frauenheilkunde. 68(6). 642–646. 3 indexed citations

13.

Untch, Michael, Steffen Kahlert, Holger Eidtmann, et al.. (2004). Anthracycline and trastuzumab in breast cancer treatment.. PubMed. 18(14 Suppl 14). 59–64. 6 indexed citations

14.

Harter, Philipp, Carmen Schade‐Brittinger, Antje Belau, et al.. (2004). AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group. Journal of Clinical Oncology. 22(14_suppl). 5081–5081. 2 indexed citations

15.

Rody, Achim, et al.. (2002). The conservative management of adnexal torsion—a case-report and review of the literature. European Journal of Obstetrics & Gynecology and Reproductive Biology. 101(1). 83–86. 56 indexed citations

16.

Minckwitz, Gϋnter von, Serban Dan Costa, Kay Friedrichs, et al.. (2002). Evidence-Based Recommendations on Primary Treatment of Carcinomas of the Breast. Zentralblatt für Gynäkologie. 124(5). 293–303. 8 indexed citations

17.

Minckwitz, G von, G. Raab, J. Hilfrich, et al.. (2001). Präoperative Chemotherapie operabler primärer Mammakarzinome mit einer dosisdichten Kombination von Adriamycin und Docetaxel (ADoc) - Die Erfahrungen der GEPARDO-GABG-Studiengruppe -. Zentralblatt für Gynäkologie. 123(9). 497–504. 4 indexed citations

18.

Costa, Serban Dan, G von Minckwitz, Günther Raab, et al.. (1999). The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.. PubMed. 26(3 Suppl 9). 24–31. 33 indexed citations

19.

Bois, Andreas du, Hans‐Joachim Lück, Werner Meier, et al.. (1997). Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.. PubMed. 24(4 Suppl 11). S11–28. 8 indexed citations

20.

Hamm, Henning, et al.. (1992). Zervixkarzinom bei HPV16-assoziierter bowenoider Papulose. Geburtshilfe und Frauenheilkunde. 52(7). 438–441. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact